SEMA6A-AS2: A Potential Drug Target and Biomarker (G105379132)

Target Name: SEMA6A-AS2

NCBI ID: G105379132

Other Name(s): Uncharacterized LOC105379132 | SEMA6A antisense RNA 2 | LOC105379132

SEMA6A-AS2: A Potential Drug Target and Biomarker

SEMA6A-AS2, a protein encoded by the SEMA6A gene located on chromosome 6, has been identified as a potential drug target and biomarker for various diseases. SEMA6A is a transmembrane protein that plays a crucial role in the development and maintenance of the nervous system, including the brain. It is involved in the regulation of cell survival, proliferation, and differentiation, and is therefore considered a potential drug target.

SEMA6A-AS2 has been shown to be highly expressed in various tissues and organs, including the brain, and has been linked to various neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative diseases. It is also has been shown to be involved in the development and progression of certain types of cancer, such as neuroblastoma and ovarian cancer. These findings suggest that SEMA6A-AS2 may be a promising biomarker and drug target for these diseases.

One of the key features of SEMA6A-AS2 is its role in the regulation of cell survival and proliferation. Studies have shown that SEMA6A-AS2 plays a role in the regulation of cell survival by preventing the formation of apoptotic cells. This is done by SEMA6A -AS2 interacting with and inhibiting the activity of pro-apoptotic enzymes, such as caspase-3 and Bax. This interaction between SEMA6A-AS2 and pro-apoptotic enzymes makes it a potential drug target for diseases characterized by the formation of apoptotic cells, such as neurodegenerative diseases.

Another feature of SEMA6A-AS2 is its role in the regulation of neuronal differentiation and plasticity. Studies have shown that SEMA6A-AS2 plays a role in the regulation of neuronal differentiation and plasticity by interacting with and modulating the activity of several transcription factors, including Dlx2 , TrkA, and Calbindin. This interaction between SEMA6A-AS2 and transcription factors makes it a potential biomarker for neuronal dysfunction and plasticity, as well as a potential drug target for diseases aimed at modulating neuronal function.

In addition to its role in cell survival and differentiation, SEMA6A-AS2 has also been shown to be involved in the regulation of cellular signaling pathways. Studies have shown that SEMA6A-AS2 interacts with and modulates the activity of several intracellular signaling pathways, including the NF-kappa pathway. This interaction between SEMA6A-AS2 and intracellular signaling pathways makes it a potential drug target for diseases characterized by the disruption of cellular signaling pathways, such as those associated with cancer and neurodegenerative diseases.

SEMA6A-AS2 has also been shown to be involved in the regulation of the blood-brain barrier. Studies have shown that SEMA6A-AS2 interacts with and modulates the activity of several proteins involved in the blood-brain barrier, including tight junction proteins and efflux pumps. This interaction between SEMA6A-AS2 and blood-brain barrier proteins makes it a potential biomarker for diseases characterized by the disruption of the blood-brain barrier, such as those associated with neurodegenerative diseases.

Overall, SEMA6A-AS2 is a protein that has been shown to be involved in several important cellular processes that are involved in the development and progression of various neurological disorders. Its interaction with pro-apoptotic enzymes, transcription factors, and intracellular signaling pathways, as well as its involvement in the regulation of the blood-brain barrier, make it a promising biomarker and drug target for

Protein Name: SEMA6A Antisense RNA 2

More Common Targets